Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 14/20 | 0.46 |
| ▸ | PTAFR | P25105 | 4/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2538074 | 0.90 | BRD4 (0.45) | BRD4PTAFR | |
| SCHEMBL2539664 | 0.89 | BRD4 (0.54) | BRD4PTAFROPRK1LMNAGABRA1 | |
| SCHEMBL2540698 | 0.87 | BRD4 (0.48) | BRD4PTAFROPRK1LMNAGABRA1 | |
| SCHEMBL2536453 | 0.87 | BRD4 (0.58) | BRD4PTAFR | |
| SCHEMBL2541447 | 0.86 | BRD4 (0.40) | BRD4PTAFROPRK1LMNAGABRA1 | |
| SCHEMBL2541831 | 0.86 | BRD4 (0.48) | BRD4PTAFROPRK1LMNAGABRA1 | |
| SCHEMBL2538815 | 0.84 | BRD4 (0.44) | BRD4 | |
| SCHEMBL2545028 | 0.84 | BRD4 (0.57) | BRD4PTAFR | |
| SCHEMBL2537873 | 0.84 | BRD4 (0.44) | BRD4PTAFROPRK1LMNAGABRA1 | |
| SCHEMBL21320337 | 0.84 | BRD4 (0.47) | BRD4PTAFROPRK1PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1887008-B1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND A MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2021-04-21 | — | — | EP | disclosed |
| US-8044042-B2 | Thienotriazolodiazepine compound and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-25 | — | — | US | disclosed |
| US-20100041643-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-02-18 | — | — | US | disclosed |
| EP-1887008-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND A MEDICINAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041643-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND MEDICINAL USE THEREOF | ICOS, CD4, CD2 | BRD4 265/4885PTAFR 231/4885OPRK1 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.